Zobrazeno 1 - 10
of 303
pro vyhledávání: ''
Autor:
Joung-Liang Lan, Huai-Chia Chuang, Jeng-Hsien Yen, Tse-Hua Tan, Pu-Ming Hsu, Yi-Ming Chen, Wei-Ting Hung
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesMAP4K3 (GLK) overexpression in T cells induces interleukin (IL)-17A production and autoimmune responses. GLK overexpressing T-cell population is correlated with severity of human systemic lupus erythematosus (SLE); however, it is unclear ho
Autor:
Faranaz Atschekzei, Maike Kosanke, Ignatius Ryan Adriawan, Reinhold E. Schmidt, Oliver Dittrich-Breiholz, Linus Risser, Panagiotis Garantziotis, Stefanie Hirsch, Torsten Witte, Georgios Sogkas
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesGiant cell arteritis (GCA) is the most common primary vasculitis, preferentially affecting the aorta and its large-calibre branches. An imbalance between proinflammatory CD4+ T helper cell subsets and regulatory T cells (Tregs) is thought t
Autor:
Denis Poddubnyy, Robert Biesen, Kay-Geert A. Hermann, Torsten Diekhoff, Fabian Proft, Felix Radny, Dominik Deppe, Katharina Ziegeler, Iris Eshed, Juliane Greese
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveTo assess the diagnostic accuracy of radiography (X-ray, XR), CT and MRI of the sacroiliac joints for diagnosis of axial spondyloarthritis (axSpA).Methods163 patients (89 with axSpA; 74 with degenerative conditions) underwent XR, CT and MR.
Autor:
Shingo Nakayamada, Satoshi Kubo, Kazuhisa Nakano, Yusuke Miyazaki, Yoshihisa Fujino, Yoshino Inoue, Yoshiya Tanaka
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesThe differences of efficacy between each Janus kinase (JAK) inhibitors have not been clarified in the patients with rheumatoid arthritis (RA) in clinical practice. Here, we compared the efficacy between tofacitinib (TOFA) and baricitinib (B
Autor:
Johanna M. W. Hazes, Wai-Kwan Lam-Tse, Angelique E. A. M. Weel, N H A M Denissen, Pascal H P de Jong, Jolanda J. Luime, T.M. Kuijper, Andreas H. Gerards, Mike H. de Jager, Elise van Mulligen, Annette H M van der Helm-van Mil
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 79(12), 1550-1556. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases, 79(12), 1550-1556. BMJ Publishing Group
Annals of the Rheumatic Diseases, 79(12), 1550-1556. BMJ PUBLISHING GROUP
Annals of the Rheumatic Diseases, 79(12), 1550-1556. BMJ Publishing Group
ObjectiveThe aim of the current study was to evaluate the 2-year cost-utility ratio between tapering conventional synthetic disease-modifying antirheumatic drugs (csDMARD) first followed by the tumour necrosis factor (TNF)-inhibitor, or vice versa, i
Autor:
Peter Wung, Yannick Allanore, Frederic Marrache, Corinne Esperet, Amel Lahmar, Dinesh Khanna, Investigators, Christopher P. Denton, Christina Soubrane, Raphael Bejuit
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesRecent advances in systemic sclerosis (SSc) show that it involves a T-helper type-2-oriented immune response with interleukin (IL)-4 and IL-13. Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neu
Autor:
Andreas Kerschbaumer, Marios Kouloumas, Suzanne H Richards, Heidi J. Siddle, Karim Raza, Lara S. Chapman, Joel Kerry, Kulveer Mankia, Daniel Aletaha, Marie Falahee, Paul Emery, Codruța Zăbălan
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesThere is increasing interest in identifying individuals at-risk of rheumatoid arthritis (RA) and initiating early treatment to prevent or delay the onset of arthritis. We aimed to describe the perceptions and experiences of at-risk individu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4edd35a9e8067d78f5f910497dd6c0d
https://eprints.whiterose.ac.uk/179217/38/annrheumdis-2021-221160.full.pdf
https://eprints.whiterose.ac.uk/179217/38/annrheumdis-2021-221160.full.pdf
Autor:
Sepideh Azarianpour, Germán Corredor, Kaustav Bera, Patrick Leo, Pingfu Fu, Paula Toro, Amy Joehlin-Price, Mojgan Mokhtari, Haider Mahdi, Anant Madabhushi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundWe present a computational approach (ArcTIL) for quantitative characterization of the architecture of tumor-infiltrating lymphocytes (TILs) and their interplay with cancer cells from digitized H&E-stained histology whole slide images and ev
Autor:
George R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, Victor Moreno, Justin Gainor, Martin J Edelman, John V Heymach, Ramaswamy Govindan, Carlos Bachier, Bernard Doger de Spéville, Matthew J Frigault, Anthony J Olszanski, Vincent K Lam, Natalie Hyland, Jean-Marc Navenot, Svetlana Fayngerts, Zohar Wolchinsky, Robyn Broad, Dzmitry Batrakou, Melissa M Pentony, Joseph P Sanderson, Andrew Gerry, Diane Marks, Jane Bai, Tom Holdich, Elliot Norry, Paula M Fracasso
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T cells (ADP-A2M10) are genetically engineered autologous T cells that express a high-affinity melanoma-associated antigen A10 (MAGE-A10)-specific T-cell receptor (TCR) targeting
Autor:
Lingfang Xia, Jin Peng, Ge Lou, Mei Pan, Qi Zhou, Wenjing Hu, Huirong Shi, Li Wang, Yunong Gao, Jianqing Zhu, Yu Zhang, Rong Sun, Xianfeng Zhou, Quanren Wang, Xiaohua Wu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundCombination treatments with immune-checkpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian canc